[Production of autologous keratinocytes for therapeutic purposes within a pharmaceutical company].
Because biotechnologies are growing and are becoming key players in the pharmaceutical industry scene, Genévrier Laboratories inaugurated in January 1998, a new department especially designed for the production of cultured cells as therapeutic agents. Meeting clinician therapeutic needs by providing autologous keratinocytes and chondrocytes in the near future, represents the primary aim of the Biotechnology department. Concrete cell-based products are already being used for the treatment of burns and cutaneous chronic wounds such as the EPIBASE graft, which corresponds to an epidermis sheet composed of cultured autologous keratinocytes.
Guillot
F L
FL
Département Biotechnologie, Laboratoires Genévrier, 280, rue de Goa, ZI Les Trois Moulins, Parc de Sophia-Antipolis, 06600 Antibes, France.
D000818:Animals; D015415:Biomarkers; D001709:Biotechnology / Q000458:organization & administration; D002056:Burns / Q000628:therapy; D018929:Cell Culture Techniques / Q000379:methods*; D002478:Cells, Cultured / Q000637:transplantation; D018920:Coculture Techniques; D004345:Drug Industry; D005347:Fibroblasts / Q000166:cytology; D005544:Forecasting; D005602:France; D006801:Humans; D015603:Keratinocytes / Q000166:cytology* / Q000637:transplantation; D051379:Mice; D011309:Preservation, Biological; D011786:Quality Control; D017768:Skin, Artificial; D013518:Surgery, Plastic; D014182:Transplantation, Autologous; D014947:Wounds and Injuries / Q000628:therapy
D015415:Biomarkers
Production de kératinocytes autologues à buts thérapeutiques au sein d'un établissement pharmaceutique.